The study will evaluate patients diagnosed with POAG or OHT who are switched to GANFORT® UD (unit dose of fixed combination bimatoprost and timolol) therapy for medical reasons in accordance with physician standard clinical practice. All treatment decisions lie with the physician.
Study Type
OBSERVATIONAL
Enrollment
1,553
Patients with POAG or OHT treated with GANFORT® UD (fixed combination bimatoprost and timolol) administered in accordance with physician standard practice for up to 12 weeks.
Unnamed facility
Wiesloch, Germany
Change From Baseline in Intraocular Pressure (IOP) in the Study Eye
IOP is a measure of the fluid pressure inside the study eye. A result at the Final Visit that is lower than the result at Baseline indicates a reduction in IOP (improvement).
Time frame: Baseline, Final Visit (Week 8 to 12)
Physician Assessment of IOP-Lowering Effect in the Study Eye Using a 3-Point Scale
The physician assessed the effectiveness of Ganfort® UD with regard to IOP changes from Baseline using a 3-point scale where: 1=Better than expected (best), 2=As expected and 3=Worse than expected. The number of participants in each category is reported.
Time frame: Baseline, Final Visit (Week 8 to 12)
Patient Assessment of Tolerability on a 4-Point Scale
The patient assessed the tolerability of Ganfort® UD using a 4-point scale where: 1=very good (best), 2=good, 3=moderate and 4=poor. The number of participants in each category is reported.
Time frame: Final Visit (Week 8 to 12)
Physician Assessment of Tolerability on a 4-Point Scale
The physician assessed the patient's tolerability of Ganfort® UD using a 4-point scale where: 1=very good (best), 2=good, 3=moderate and 4=poor. The number of participants in each category is reported.
Time frame: Final Visit (Week 8 to 12)
Percentage of Patients Who Discontinued Treatment
The percentage of participants who discontinued treatment with Ganfort® UD up to the Week 12 Final Visit
Time frame: 12 Weeks
Percentage of Patients Prescribed by the Physician to Continue Treatment
The percentage of participants who continued treatment with Ganfort® UD after Week 12.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Final Visit (Week 8 to 12)
Physician Assessment of Patient Compliance Compared to Previous Treatment on a 3-Point Scale
The physician assessed patient compliance with Ganfort® UD compared to previous treatment using a 3-point scale where: 1=better (best), 2=equal and 3=worse. The number of participants in each category is reported.
Time frame: Final Visit (Week 8 to 12)